Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Novocure Ltd - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
NVCR
Nasdaq
2836
https://www.novocure.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Novocure Ltd
Why Novocure Stock Is Jumping Today
- Mar 28th, 2024 3:50 pm
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
- Mar 28th, 2024 9:01 am
Novocure Surges 12% On Brain Tumors Study; But Some Analysts Are Bearish
- Mar 27th, 2024 8:08 pm
UPDATE 1-Novocure's lung cancer therapy succeeds in late-stage trial
- Mar 27th, 2024 11:14 am
Novocure's device shown to slow cancer progression in the brain in trial
- Mar 27th, 2024 11:12 am
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
- Mar 27th, 2024 11:00 am
Does NovoCure (NVCR) Have the Potential to Rally 63.51% as Wall Street Analysts Expect?
- Mar 13th, 2024 1:55 pm
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
- Mar 11th, 2024 11:00 am
Is NovoCure Limited (NASDAQ:NVCR) Worth US$16.0 Based On Its Intrinsic Value?
- Feb 29th, 2024 12:26 pm
NovoCure Limited (NASDAQ:NVCR) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:43 pm
NovoCure (NVCR) Q4 2023 Earnings Call Transcript
- Feb 22nd, 2024 5:15 pm
NovoCure (NVCR) Reports Q4 Loss, Tops Revenue Estimates
- Feb 22nd, 2024 1:25 pm
NovoCure Ltd (NVCR) Reports Mixed Financial Results for Q4 and Full Year 2023
- Feb 22nd, 2024 12:36 pm
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- Feb 22nd, 2024 12:00 pm
Strength Seen in NovoCure (NVCR): Can Its 16.8% Jump Turn into More Strength?
- Jan 19th, 2024 12:46 pm
Why Is Cancer Focused Novocure Stock Trading Higher Today?
- Jan 18th, 2024 7:19 pm
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
- Jan 18th, 2024 12:00 pm
Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know
- Jan 11th, 2024 2:55 pm
GoodRx Holdings, Inc. (GDRX) Surges 13.3%: Is This an Indication of Further Gains?
- Jan 11th, 2024 11:07 am
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
- Jan 9th, 2024 12:00 pm
Scroll